Catch up on today's top five analyst upgrades with this list compiled by The Fly: Home Depot (HD) upgraded to Outperform from Market Perform at Raymond James with analyst Budd Bugatch saying the company continues to execute at a "world-class level." 2. Mylan (MYL) upgraded to Buy from Neutral at Citi with analyst Liav Abraham saying the company is best positioned to execute in a challenging operating environment for generics. 3. Biogen (BIIB) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Terence Flynn saying he continues to see optionality Aducanumab, its lead pipeline Alzheimer's drug. 4. Zions Bancorp (ZION) upgraded to Buy from Neutral at BofA/Merrill with analyst Erika Najarian saying she believes investors are discounting two catalysts for earnings upside including benefits from regulatory reform for regionals and continued improvement in expense management. 5. Paychex (PAYX) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Danyal Hussain saying expectations adequately capture downside risks and the valuation premium is the lowest since 2008. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

Wedbush analyst Laura Chico raised the firm's price target on Biogen to $215 from $213 and keeps a Neutral rating on the shares. It remains early days for newly launching products like Skyclarys, Leqembi and Zurzuvae, the firm notes. That being said, it is encouraging to start to see revenue growth for Leqembi and continued growth for Skyclarys. Wedbush continues to see a gap between the newly launching products and earlier-stage development programs that will need to be addressed. However, larger-scale BD deals are likely easier to complete in 2025.

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here

UBS lowered the firm's price target on Zions Bancorp to $45 from $47 and keeps a Neutral rating on the shares. While "impressed" by Zions' ability to control deposit costs in a competitive backdrop, the firm thinks the liability sensitive positioning potentially puts the bank in "a precarious spot" in a higher-for-longer rate scenario and coming out of Q1 earnings the firm says it gets the sense that the net interest income trajectory from here is "well understood by the Street."